The present application relates to methods for the generation of human pluripotent stem cell- derived cells involved in haematopoiesis and lymphopoiesis, such as arterial endothelial cells, innate lymphoid cells, natural killer (NK)-like cells, and T cells. The present application also relates to haemogenic arterial endothelial cells, innate lymphoid cells, natural killer (NK)-like cells, T cells and erythroid cells and myeloid cells, and progenitors of such cells, produced by such methods.
Methods of measuring chimerism in a biological sample use informative copy number variations (CNV) in genetically distinct cell populations. Chimerism describes the co-existence of cells originating from more than one individual. Assessing CNV polymorphisms in genomic DNA provides a useful in-vitro method of measuring chimerism. The accuracy of the methods can be validated using an internal validation step.
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
The present disclosure provides a method for determining whether a subject is at risk of delayed recovery from mild traumatic brain injury (mTBI), the method comprising: (1) obtaining a sample biomarker profile of a subject, wherein the sample biomarker profile evaluates at least one biomarker; (2) comparing the sample biomarker profile to a reference biomarker profile, wherein the reference biomarker profile evaluates, for an individual biomarker in the sample biomarker profile, a corresponding biomarker; and (3) determining whether the subject is at risk of delayed recovery from mTBI based on the comparison of the sample biomarker profile and the reference biomarker profile. Also disclosed herein are methods of correlating a biomarker profile with a positive or negative response to a treatment regimen for mTBI, methods of stratifying a subject determined to be at risk of delayed recovery from mTBI to a treatment regimen; methods of treating a subject determined to be at risk of delayed recovery from mTBI; kits and uses thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (Australie)
Inventeur(s)
Porello, Enzo
Brizard, Christian
Hudson, James Edward
Mathieson, Ellen Frances
Laskary, Andrew
Reynolds, Liam
Abrégé
The present application relates to methods for the generation of engineered human pluripotent stem cell-derived cardiac tissue, engineered cardiac tissue produced by such methods and methods for their use.
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australie)
MURDOCH CHILDREN'S RESEARCH INSTITUTE (Australie)
DEAKIN UNIVERSITY (Australie)
Inventeur(s)
Szmulewicz, David Joshua
Pathirana, Pubudu Nishantha
Krishna, Ragil
Corben, Louise Anne
Horne, Malcolm Kenneth
Abrégé
A movement monitoring system for objectively quantifying a motor control disorder in a subject comprises a movement detection device generating movement data representing movement of a limb of the subject and an analyser for analysing the movement data. The movement detection device comprises sensors measuring at least motion of the device and pressure applied to the device by the subject. The analyser comprises a processor and a memory containing code which, when executed by the processor, receives the movement data generated by the movement detection device, applies the received movement data to an algorithmic model stored in the memory and identifies one or more features from the movement data that represent disordered movement by the subject, and calculates from the one or more identified features a score corresponding to the existence of the motor control disorder in the subject.
The invention relates to an isolated cell having, after culturing a pluripotent stem cell (PSC) in a medium comprising a WNT agonist and an ACTIVIN antagonist, increased HOXA gene expression relative to a PSC not cultured in a medium comprising a WNT agonist and an ACTIVIN antagonist, wherein the cell with increased HOXA gene expression is capable of generating a definitive haematopoietic stem/precursor cell. The invention also relates to use of the cell for generating a definitive haematopoietic stem/precursor cell, and a method for differentiating a PSC into a definitive haematopoietic stem/precursor cell and a definitive haematopoietic stem/progenitor cell differentiated from a PSC by the method. The invention further relates to a therapeutic composition comprising a cell of the invention, and to therapeutic methods and uses of a cell of the invention. The invention also relates to a reporter cell comprising distinguishable SOX17 and RUNXIC reporters, for use in tracking the differentiation of a PSC into a definitive haematopoietic stem/progenitor cell.
The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.
A method of detecting circulatory nucleic acids from a transplanted tissue in a transplant recipient, the method comprising: amplifying circulatory nucleic acids from a transplanted tissue in a blood sample from the transplant recipient, and detecting amplification of a copy number deletion (CND) polymorphism from the transplanted tissue, and related methods for determining the status of a donor tissue transplanted into a recipient.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
The present application relates to methods for inducing the differentiation of stem cells into chondrocyte progenitors and chondrocytes in vitro. The methods also relate to the production of in vitro-engineered cartilage and bone and related biomaterials as well as methods of drug-screening and modelling of bone- and cartilage-related diseases and disorders.
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present application relates to methods for inducing the differentiation of stem cells into chondrocyte progenitors and chondrocytes in vitro. The methods also relate to the production of in vitro-engineered cartilage and bone and related biomaterials as well as methods of drug-screening and modelling of bone- and cartilage-related diseases and disorders.
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The present disclosure relates to bio-printed kidney tissue and methods of manufacturing the same. The bio-printed tissue and methods may be used in a variety of applications such as regenerative medicine.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australie)
MURDOCH CHILDREN'S RESEARCH INSTITUTE (Australie)
DEAKIN UNIVERSITY (Australie)
Inventeur(s)
Szmulewicz, David Joshua
Pathirana, Pubudu Nishantha
Krishna, Ragil
Corben, Louise Anne
Horne, Malcolm Kenneth
Abrégé
A movement monitoring system for objectively quantifying a motor control disorder in a subject comprises a movement detection device generating movement data representing movement of a limb of the subject and an analyser for analysing the movement data. The movement detection device comprises sensors measuring at least motion of the device and pressure applied to the device by the subject. The analyser comprises a processor and a memory containing code which, when executed by the processor, receives the movement data generated by the movement detection device, applies the received movement data to an algorithmic model stored in the memory and identifies one or more features from the movement data that represent disordered movement by the subject, and calculates from the one or more identified features a score corresponding to the existence of the motor control disorder in the subject.
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Australie)
MURDOCH CHILDREN'S RESEARCH INSTITUTE (Australie)
DEAKIN UNIVERSITY (Australie)
Inventeur(s)
Pathirana, Pubudu, Nishantha
Krishna, Ragil
Corben, Louise, Anne
Horne, Malcolm, Kenneth
Abrégé
A movement monitoring system for objectively quantifying a motor control disorder in a subject comprises a movement detection device generating movement data representing movement of a limb of the subject and an analyser for analysing the movement data. The movement detection device comprises sensors measuring at least motion of the device and pressure applied to the device by the subject. The analyser comprises a processor and a memory containing code which, when executed by the processor, receives the movement data generated by the movement detection device, applies the received movement data to an algorithmic model stored in the memory and identifies one or more features from the movement data that represent disordered movement by the subject, and calculates from the one or more identified features a score corresponding to the existence of the motor control disorder in the subject.
The invention relates to the treatment and prevention of problem behaviour by the administration of a composition that includes an effective amount of Prevotella.
The present disclosure relates to bio-printed kidney tissue and methods of manufacturing the same. The bio-printed tissue and methods may be used in a variety of applications such as regenerative medicine.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
B33Y 80/00 - Produits obtenus par fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
The present disclosure relates to bio-printed kidney tissue and methods of manufacturing the same. The bio-printed tissue and methods may be used in a variety of applications such as regenerative medicine.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
B33Y 80/00 - Produits obtenus par fabrication additive
The invention relates to a method for producing a lymphocyte progenitor, the method comprising culturing a pluripotent stem cell (PSC)-derived CD34+ cell at an air-liquid interface (ALI). The invention also relates to a method for producing a B-cell progenitor, the method comprising co-culturing a PSC-derived CD34+ cell and a stromal cell in a medium comprising a CD117 activator and a NOTCH1 inhibitor. The invention further relates to a T-cell progenitor and a B-cell progenitor when produced by the methods of the invention and to use of the T-cell progenitor in the manufacture of T cell with defined antigen specificity, optionally a chimeric antigen receptor (CAR) T cell, and use of the B-cell progenitor in the manufacture of an antibody.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
The present disclosure relates to kidney organoids and methods of manufacturing the same. The organoids and methods may be used in a variety of applications such as disease modelling, drug screening, regenerative medicine and 5 scaling up production of kidney cells.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention relates to assays, methods and kits for determining the efficacy of one or more pharmaceutical agents for improving mitochondrial function in an individual.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
The present disclosure relates generally to methods for determining whether a subject has, or is likely to have, desensitisation, sustained unresponsiveness or long-term sustained unresponsiveness (tolerance) to a food allergen following cessation of oral immunotherapy (OIT) for a food allergy, the method comprising measuring at least one food allergen specific immunoglobulin level from a sample of a subject at a time point relative to the start of OIT, and analysing the at least one allergen specific immunoglobulin level based on modelled subject OIT immunoglobulin levels to determine whether the subject has, or is likely to have, desensitisation, sustained unresponsiveness or long-term sustained unresponsiveness to the food allergen following cessation of OIT.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OE VETERANS AFFAIRS (USA)
Inventeur(s)
Little, Melissa
Vanslambrouck, Jessica
Woodard, Lauren
Wilson, Matthew
Abrégé
Expression of exogenous SNAI2, EYA1 and SIX1 genes in a cell, tissue or organ not normally having nephron progenitor activity, induces or re-programs that cell to have or subsequently develop nephron progenitor activity. Nephron progenitors induced 5 by expression of SNAI2, EYA1 and SIX1 may be used for the production of nephron cells and tissues that are useful in treatment of kidney disorders, kidney regeneration, kidney transplantation, bioprinting and nephrotoxocity testing.
The invention relates to the treatment and prevention of problem behaviour by the administration of a composition that includes an effective amount of Prevotella.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
The invention relates to the treatment and prevention of problem behaviour by the administration of a composition that includes an effective amount of Prevotella.
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present disclosure relates to an isolated 3D organoid glomerulus, wherein the glomerulus is isolated from a stem cell-derived kidney organoid. These structures may be used in a variety of applications such as disease modelling, drug screening and toxicity screening.
The present disclosure relates to kidney organoids and methods of manufacturing the same. The organoids and methods may be used in a variety of applications such as disease modelling, drug screening, regenerative medicine and 5 scaling up production of kidney cells.
The present disclosure relates to kidney organoids and methods of manufacturing the same. The organoids and methods may be used in a variety of applications such as disease modelling, drug screening, regenerative medicine and 5 scaling up production of kidney cells.
The present disclosure relates to methods of amplifying a target sequence in a sample using competitive priming. Such methods may be suitable for detecting sequence variants and diagnosing various pathologies as well as quantifying the level of these rare events that may be missed on the more abundant wildtype sequence background.
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Little, Melissa
Vanslambrouk, Jessica
Woodard, Lauren
Wilson, Matthew
Abrégé
Expression of exogenous SNAI2, EYA1 and SIX1 genes in a cell, tissue or organ not normally having nephron progenitor activity, induces or re-programs that cell to have or subsequently develop nephron progenitor activity. Nephron progenitors induced 5 by expression of SNAI2, EYA1 and SIX1 may be used for the production of nephron cells and tissues that are useful in treatment of kidney disorders, kidney regeneration, kidney transplantation, bioprinting and nephrotoxocity testing.
The invention relates to a method for producing a lymphocyte progenitor, the method comprising culturing a pluripotent stem cell (PSC)-derived CD34+ cell at an air-liquid interface (ALI). The invention also relates to a method for producing a B-cell progenitor, the method comprising co-culturing a PSC-derived CD34+ cell and a stromal cell in a medium comprising a CD117 activator and a NOTCH1 inhibitor. The invention further relates to a T-cell progenitor and a B-cell progenitor when produced by the methods of the invention and to use of the T-cell progenitor in the manufacture of T cell with defined antigen specificity, optionally a chimeric antigen receptor (CAR) T cell, and use of the B-cell progenitor in the manufacture of an antibody.
The invention relates to a method for producing a lymphocyte progenitor, the method comprising culturing a pluripotent stem cell (PSC)-derived CD34+ cell at an air-liquid interface (ALI). The invention also relates to a method for producing a B-cell progenitor, the method comprising co-culturing a PSC-derived CD34+ cell and a stromal cell in a medium comprising a CD117 activator and a NOTCH1 inhibitor. The invention further relates to a T-cell progenitor and a B-cell progenitor when produced by the methods of the invention and to use of the T-cell progenitor in the manufacture of T cell with defined antigen specificity, optionally a chimeric antigen receptor (CAR) T cell, and use of the B-cell progenitor in the manufacture of an antibody.
The present disclosure relates to an absorbent article comprising a liquid permeable bodyside liner; an outer cover; and an absorbent body positioned between the bodyside liner and the outer cover for detecting the presence of bilirubin in urine and stabilised enzymes for use in the same. Bilirubin oxidase may be stabilised by covalently binding to one or more polymers such as polyacrylic acid. Such absorbent articles incorporating said enzymes may be used to detect jaundice in a subject.
A61L 15/38 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des enzymes
A61F 13/15 - Garnitures absorbantes, p.ex. serviettes ou tampons hygiéniques pour application externe ou interne au corps; Moyens pour les maintenir en place ou les fixer; Applicateurs de tampons
G01N 33/493 - Analyse physique de matériau biologique de matériau biologique liquide d'urine
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
34.
METHODS AND COMPOSITIONS FOR DETERMINING, AND FOR MINIMIZING, THE LIKELIHOOD OF DEVELOPMENT OF ALLERGY IN INFANTS
The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
Inventeur(s)
Konstantinov, Igor E.
Smyth, Gordon K.
Abrégé
The present disclosure relates to methods of detecting organ transplant rejection based on the level of gene expression in a sample isolated from an organ transplant recipient. In particular, the present disclosure relates to methods of grading organ transplant rejection. The present disclosure also relates to methods of resolving inconclusive pathology to detect and/or grade transplant rejection.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention relates to an isolated cell having, after culturing a pluripotent stem cell (PSC) in a medium comprising a WNT agonist and an ACTIVIN antagonist, increased HOXA gene expression relative to a PSC not cultured in a medium comprising a WNT agonist and an ACTIVIN antagonist, wherein the cell with increased HOXA gene expression is capable of generating a definitive haematopoietic stem/precursor cell. The invention also relates to use of the cell for generating a definitive haematopoietic stem/precursor cell, and a method for differentiating a PSC into a definitive haematopoietic stem/precursor cell and a definitive haematopoietic stem/progenitor cell differentiated from a PSC by the method. The invention further relates to a therapeutic composition comprising a cell of the invention, and to therapeutic methods and uses of a cell of the invention. The invention also relates to a reporter cell comprising distinguishable SOX17 and RUNXIC reporters, for use in tracking the differentiation of a PSC into a definitive haematopoietic stem/progenitor cell.
The invention relates to an isolated cell having, after culturing a pluripotent stem cell (PSC) in a medium comprising a WNT agonist and an ACTIVIN antagonist, increased HOXA gene expression relative to a PSC not cultured in a medium comprising a WNT agonist and an ACTIVIN antagonist, wherein the cell with increased HOXA gene expression is capable of generating a definitive haematopoietic stem/precursor cell. The invention also relates to use of the cell for generating a definitive haematopoietic stem/precursor cell, and a method for differentiating a PSC into a definitive haematopoietic stem/precursor cell and a definitive haematopoietic stem/progenitor cell differentiated from a PSC by the method. The invention further relates to a therapeutic composition comprising a cell of the invention, and to therapeutic methods and uses of a cell of the invention. The invention also relates to a reporter cell comprising distinguishable SOX17 and RUNXIC reporters, for use in tracking the differentiation of a PSC into a definitive haematopoietic stem/progenitor cell.
The invention relates to an isolated osteoarthritis miRNA, or an ortholog thereof, and to mimics and inhibitors thereof. The invention also relates to use of the osteoarthritis miRNAs, mimics and inhibitors thereof for diagnosing and/or treating osteoarthritis in subject.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
40.
SYSTEMS AND COMPUTER-IMPLEMENTED METHODS FOR ASSESSING SOCIAL COMPETENCY
An assessment system for assessing social competency of a user of the assessment system. The assessment system comprises at least one processor, a user interface and memory comprising program code, which when executed by the at least one processor is configured to provide an assessment platform to the user interface. The memory comprises an assessment application including a games module and an assessment module. The games module includes at least one interactive game component in each of at least three social domains, each of the interactive game components, when executed by the at least one processor, being configured to provide an interactive game to the assessment platform and to determine an outcome for the interactive game based on user inputs received from the user of the assessment system via the user interface. The assessment module, when executed by the at least one processor, is configured to assess social competency of the user of the assessment platform based on the outcome of at least one interactive game in each of the at least three social domains and to generate an assessment outcome. The at least three social domains comprise attention/executive function, communication, and social cognition.
The invention relates to the treatment of inflammatory bowel disease characterised by chronic inflammation. In particular, the invention relates to methods of predicting, treating or preventing post-operative recurrence of Crohn's disease.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure relates to methods and assays for detecting a food allergy or a propensity to develop a food allergy in a subject based on gene methylation status.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
45.
VECTORS AND METHODS FOR TARGETED INTEGRATION IN LOCI COMPRISING CONSTITUTIVELY EXPRESSED GENES
The invention relates to a vector comprising: a 5' nucleic acid that is homologous to a genomic sequence 5' of a stop codon of a constitutively expressed gene; an exogenous nucleic acid; a 3' nucleic acid that is homologous to a genomic sequence 3' of the stop codon of the constitutively expressed gene; a translation interruption-reinitiation signal operably linked to the 5' nucleic acid and the exogenous nucleic acid, wherein the translation interruption-reinitiation signal is capable of replacing the stop codon of the constitutively expressed gene.
The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREE3, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G06F 19/24 - pour l'apprentissage automatique, l'exploration de données ou les bio statistiques, p.ex. détection de motifs, extraction de connaissances, extraction de règles, corrélation, agrégation ou classification
The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
The present disclosure relates generally to the field of viral vaccines. Particularly, the present disclosure provides a modified Vero-adapted human rotavirus strain and a culturing method to produce high titer virus, a rotavirus vaccine, vaccination protocols and diagnostic and prognostic assays.
C12N 7/04 - Inactivation ou atténuation; Production de parties élémentaires de virus
A61K 39/15 - Reoviridae, p.ex. virus de la diarrhée du veau
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
49.
A QUANTITATIVE ASSAY FOR TARGET DNA IN A MIXED SAMPLE COMPRISING TARGET AND NON-TARGET DNA
The present disclosure relates generally to an assay to detect and quantitate target nucleic acid in a mixture of target and non-target nucleic acid, kits useful for same and its use in non-invasive diagnostic methodologies. The assay comprises identifying copy number variation (CNV) polymorphisms present in the target nucleic acid and absent in non-target nucleic acid. Embodiments disclosed include quantitating the level of fetal DNA in sample of maternal DNA and fetal DNA, and quantitating the level of donor-derived DNA in sample from a transplant recipient comprising self DNA and non-self or donor DNA.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Australie)
MURDOCH CHILDRENS RESEARCH INSTITUTE (Australie)
Inventeur(s)
Blewitt, Marnie
Harrison, Leonard Charles
Maksimovic, Jovana
Naselli, Gaetano
Oshlack, Alicia
Zhang, Yuxia
Abrégé
A method for identifying the level of T-regulatory cell activity in a test biological sample comprising immune cells, the method comprising screening a test sample for the methylation profiles of a pre-selected genetic locus/loci selected from the list consisting of: (i) at least one genetic locus or at least two genetic Loci defined m one or more of Table 1 to Table 5; (ii) at least one genetic locus or at least two genetic loci defined in one or more of Table 6 to Table 10; and (iii) at least two genetic loci defined in one or more of Table 1 to Table 5, and one or more of Table 6 to Table 10; and determining the degree of concordance between the test methylation profiles and a reference methylation profile, wherein the degree of concordance identifies the level of T-regulatory cell activity in the sample.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
51.
AN ASSAY FOR QUANTITATING THE EXTENT OF METHYLATION OF A TARGET SITE
The present specification relates to an assay to quantitate extent of methylation in a DNA sample. Kits and clinical diagnostic assays are also enabled herein including assays to determine clinical phenotypes based on extent of methylation of a DNA target site.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G06F 19/22 - pour la comparaison de séquences impliquant des nucléotides ou des acides aminés, p.ex. recherche d'homologie, identification de motifs ou de polymorphismes de nucléotides simples [SNP] ou alignement de séquences
The present disclosure relates generally to the field of viral vaccines. Particularly, the present disclosure provides a modified Vero-adapted human rotavirus strain and a culturing method to produce high titer virus, a rotavirus vaccine, vaccination protocols and diagnostic and prognostic assays.
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australie)
MURDOCH CHILDRENS RESEARCH INSTITUTE (Australie)
Inventeur(s)
Samuel, Chrishan
Hewitson, Tim
Abrégé
The present invention provides pharmaceutical compositions comprising at least one relaxin polypeptide and at least one ACE inhibitor for use in the treatment of fibrosis and fibrotic diseases and in reducing or preventing the progression of pre-existing fibrosis. The invention also provides methods of treatment using such compositions.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
54.
DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION STATUS
The present disclosure relates generally to tissue, including organ, transplantation. Taught herein is a genetic-based diagnostic assay to ascertain the status of a tissue transplantation procedure in a recipient based on a characterization of circulating or other cell free nucleic acid material. The instant disclosure enables kits, primers and protocols for ascertaining the status of a transplantation procedure.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
55.
TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS
The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. Epigenetic profiles are disclosed from the following sites in the FMR1 gene: FREE3, intron 2, an intron, intron/exon boundary and/or splicing region downstream of intron 2, and a site within the FREE2 portion of intron 1 in combination with a FM. Epigenetic profiles are also disclosed from a region in the FMR genetic locus selected from an intron, intron/exon boundary, a splicing region or an intragenic region in combination with an expansion mutation. Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure relates generally to the field of immunological-based diagnostic assays to detect infection and stage of infection by pathogens. Taught herein is an assay to detect mycobacterial infection and to distinguish between active and latent forms of mycobacterial infection. Kits and therapeutic protocols are also enabled by the present disclosure.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
57.
SYSTEM AND PROCESS FOR DETERMINING A POSITIVE END-EXPIRATORY PRESSURE FOR A MECHANICAL VENTILATION SYSTEM
A process for determining a positive end-expiratory pressure for a mechanical ventilation system, including: determining values for compliance of a patient's respiratory system during mechanical ventilation of the patient using respective positive end-expiratory pressure (PEEP) values; and processing the compliance values and the PEEP values to determine a PEEP value as substantially being a lowest PEEP value that provides a highest compliance value.
A method of treating a waste evacuation dysfunction comprising administering transcutaneous electrical stimulation (TES) to at least one lower pelvic and/or sacral region for a specific treatment regimens. Also disclosed is a system for configuring a stimulation device to deliver transcutaneous electrical stimulation (TES) the system comprising: a computing device storing or having access to a plurality or TES settings and comprising a user interface to enable authorised selection of at least on of the TES settings for provision of TES by the stimulation device according to the at least one selected TES setting and the stimulation device communicatively coupled to the computing device to receive and store the selected at least one TES setting the stimulation device being of a size to be readily carried on a body and configured to selectively provide current to external electrode according to the one TES setting.
A61N 1/24 - Ceintures électromédicales avec source de courant incorporée
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
The present disclosure teaches the treatment of a blood pathology, such as a blood pathology associated with impaired hemoglobin synthesis including the treatment of β-thalassemia or a related hemoglobinopathy. An RNA molecule such as a short interfering RNA or a hairpin RNA which targets an mRNA species encoding α-globin is administered to a subject to reduce the amount of α-globin produced to non-zero levels and ameliorate the effects of an α- and β-globin chain imbalance.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present disclosure relates generally to an assay for the determination of epigenetic profiles including epigenetic profiles associated with a pathological condition. The present disclosure teaches an assay to detect epigenetic profiles associated with cancer including its form or type, state and minimum residual disease status. The assay enabled herein further identifies and monitors forms and sub-types of leukemia and other hematological malignancies. Kits and assays for medicaments are also taught herein. Methods for screening agents which modulate methylation are also enabled.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 50/06 - Procédés biochimiques, p.ex. utilisant des enzymes ou des micro-organismes viables entiers
61.
TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS
The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREE3, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A therapeutic ischemic and reperfusion device with an associated monitoring system for generally enhancing the vascular and metabolic environment and wellbeing of a subject. A method for the treatment and prophylaxis of various medical conditions including environmental induced oxidative stress using the therapeutic ischemic and reperfusion device and associated monitoring system is also contemplated herein. The method uses an inflatable cuff around the limb or torso of a subject operated by a controller configured to inflate and deflate the cuff. The monitoring system is used to monitor the physical and metabolic environments of the subject during and subsequent to the ischemia and reperfusion.
The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Some embodiments relate to a method of treating a waste evacuation dysfunction, comprising administering transcutaneous electrical stimulation to at least one lumbar or abdominal region for at least one treatment period per day over a treatment term of at least one week.
The present invention relates generally to biomarkers of neurological conditions including monitoring disease progression and the clinical severity of symptoms. More particularly, the present invention provides an assay to facilitate diagnosis and monitoring of progression of neurological conditions and treatment response and to identify targets for therapeutic intervention. Kits and assays for diagnosis and identification of medicaments also form part of the present invention.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present invention relates generally to an assay for the determination of epigenetic profiles, particularly epigenetic profiles associated with a pathological condition. Even more particularly, the present invention provides an assay to detect epigenetic profiles within the Fragile X Mental Retardation (FMR) genetic locus indicative of a pathoneurological condition such as pathoneurodevelopmental and pathoneurodegenerative conditions. The epigenetic profiles can also identify potential non-neurological conditions. Kits and assays for medicaments also form part of the present invention as do computer programs to monitor changes in epigenetic patterns and methods for screening for agents which modulate epigenetic modification.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates generally to the field of sex determination of animals. Provided are methods and agents to manipulate sex determination, particularly in avian animals such as chickens, through a male chromosome-linked testis (sex) regulatory gene. Expression or activity of the DMRT1 gene or protein is modulated to produce animals with displaying a phenotype sex that differs from their genotype.
The present invention relates generally to the field of cellular differentiation and its uses, such as in cell therapy, diagnostics and screening assays for medicaments.
A system for analysis and interpretation of movement data, comprising: i. a variable difference score (VDS) generator for generating VDS data, representing variable difference scores, based on the difference between a first trace and a second trace, both traces relating to a selected movement variable of one or more animals; and ii. a movement analysis profile (MAP) generator for generating MAP data, representing a movement analysis profile for the animal, based on at least two of the variable difference scores in the generated VDS data.
G06Q 50/00 - Systèmes ou procédés spécialement adaptés à un secteur particulier d’activité économique, p.ex. aux services d’utilité publique ou au tourisme
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61D 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
The present invention relates to methods for the detection and treatment of a sensory neuropathy in a mammal, including a human, comprising screening for a mutation in the Synaptojanin-2 gene or its expression product. More particularly, the present invention provides diagnostic assays and therapeutic targets for hearing impairment or other sensory neuropathies. Animal models of deafness are also provided.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 27/00 - Médicaments pour traiter les troubles des sens
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/42 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase une phosphatase
The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The present invention relates generally to diagnostic assays, therapeutic protocols and medicinal predictor model validation. More particularly, genetic tests are provided which determine the suitability of a medicament in the treatment or prophylaxis of a neurological condition. Even more particularly, the present invention provides genetic assays to measure the potential for, or likelihood of, a subject having a positive or adverse treatment response to a neurological medicament. The present invention is particularly useful in the practice of personalized medicine.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
The present invention relates generally to a method for identifying or distinguishing one type of cell from other cells within a population of cells. The present invention further provides the detection, monitoring and isolation of sub- populations cell types within a population of cells including a biological entity comprising such cell types. Kits, diagnostic agents and panels of nucleic acid probes for identifying and distinguishing cell types also form part of the present invention. The detection of particular cell types is based upon the use of a labelled probe that hybridizes to chromosomal DNA at the flanking sequences of a deletion. Alternatively two probes with distinguishable reporter molecules are used wherein only one probe is capable of hybridizing to chromosomal DNA in one cell type whereas both are capable of hybridizing to chromosomal DNA in another cell type. The methods are useful in the identification of cells with copy number variations, chromosomal deletions, additions or aberrations.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates generally to a method for profiling or stratifying an individual or group of individuals with respect to a mental health condition including a psychiatric, neurological or psychological condition, phenotype or state, said method comprising determining the presence or absence or extent of DNA methylation of the 5HTT promoter region and/or the level of expression of the 5HTT gene alone or in combination with the presence or absence or number of S-allelic forms of the 5HTT gene. Methods for the treatment or prophylaxis of a mental health condition including a psychiatric, neurological or psychological condition, phenotype or state are also contemplated together with therapeutic agents and protocols useful for same.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
75.
A THERAPEUTIC PROTOCOL USING STEM CELLS IN TISSUE AND NEURONAL REPAIR, MAINTENANCE, REGENERATION AND AUGMENTATION
The present invention relates generally to the field of tissue and neuronal repair, maintenance, regeneration and augmentation. More particularly, the present invention encompasses an improved stem cell therapeutic protocol.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
76.
THERAPEUTIC PROTOCOL FOR TREATING HEMOGLOBINOPATHY
The invention identifies compounds which influence the activity of the &ggr;-globin gene promoter and thus expression of the &ggr;-globin gene. Such compounds are proposed to be useful in therapeutic protocols for treating hemoglobinopathy by induction of fetal hemoglobin production. The compound is selected from the group consisting of (i) a nucleoside analog; (ii) a nucleotide analog; or (iii) a compound selected from the group consisting of 4-acetoxyphenol, penicillic acid, hydroquinone, erysolin, diaziquone, aclacinomycin Al, thiotepa, 4-hydroxychalcone, melphalan, 6,3-dimethoxyflavone, 3-desmethyly-5-deshydroxyscleroin, isoliquiritigenin, pipobroman, hematoporphyrin dihydrochloride and quercetin and (iv) a combination of (i), (ii) and/or (iii) wit the proviso that the subject is not infected with HIV or has a condition characterised by polymerization of hemoglobin in the cells of the subject.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/235 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide non condensés avec un autre cycle, p.ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p.ex. dérivés de la porphine, bilirubine, biliverdine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
77.
FRAGMENTS OF VON WILLEBRAND FACTOR A-RELATED PROTEIN
THE MURDOCH CHILDRENS RESEARCH INSTITUTE (Australie)
Inventeur(s)
Bateman, John
Fitzgerald, David, James
Abrégé
The present invention relates generally to bioactive molecules. More particularly, the present invention provides fragments of, or fractions comprising fragments of, von Willebrand Factor A-Related Protein (WARP) or a homolog, analog, derivative, mimetic or functional equivalent thereof. The fragments or fractions have a range of biochemical, physiological and/or pharmacological activities including, inter alia, activities associated with stem cell proliferation, differentiation and self-renewal, coagulation, hemeostasis, control of cancer growth and angiogenesis. The present invention further provides pharmaceutical compositions comprising the bioactive molecules or homologs, analogs, derivatives, mimetics or functional equivalents thereof. The present invention still further provides methods for preventing and/or treating a range of diseases and conditions in a subject by the administration of the bioactive molecules or homologs, analogs, derivatives, mimetics or functional equivalents thereof. In still yet further embodiments, the present invention provides diagnostic assays and coating materials for medical devices such as stents, catheters and the like.
The present invention discloses the use of modified IGFBP-2 and agents that regulate the interaction between HBD of IGFBP-2 and EC or PC matrix components to prevent cellular proliferation invasion and/or migration (metastases).
brevets
